Log in

Relevant bibliographies by topics / Rabeprazole / Journal articles

To see the other types of publications on this topic, follow the link: Rabeprazole.

Journal articles on the topic 'Rabeprazole'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Rabeprazole.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Cusimano, Joseph. "Rabeprazole." WikiJournal of Medicine 9, no. 1 (2022): 6. http://dx.doi.org/10.15347/wjm/2022.006.

Full text

Abstract:

Rabeprazole is a proton pump inhibitor that suppresses gastric acid production in the stomach. Available under different brand name products as well as in a variety of combination products, rabeprazole has several medical uses concerning the management of problems of pathological gastric acid. Rabeprazole's adverse effects tend to be mild but can be serious, including deficiencies in essential nutrients, rare incidences of liver damage, and immune-mediated reactions. As a class effect, rabeprazole can increase the risk for osteoporosis, serious infections (including Clostridium difficile infec

APA, Harvard, Vancouver, ISO, and other styles

2

Duan, Zhenya, Yan Wang, Ling Zhang, et al. "An application of continuous flow microreactor in the synthesis and extraction of rabeprazole." International Journal of Chemical Reactor Engineering 19, no. 3 (2021): 287–94. http://dx.doi.org/10.1515/ijcre-2020-0173.

Full text

Abstract:

Abstract The oxidation of rabeprazole sulfide is a key step in the synthesis of rabeprazole, a drug for the treatment of stomach acid-related disorders. The current rabeprazole production process adopts one pot batch process, which has low reaction efficiency and poor stability. A continuous process can greatly improve the production efficiency and solve the above problems. Therefore, the reaction parameters of rabeprazole in microreactor were explored through laboratory experiments to explore the possibility of continuous production of rabeprazole. Rabeprazole sodium was synthesized by using

APA, Harvard, Vancouver, ISO, and other styles

3

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1394 (2012): 35. http://dx.doi.org/10.2165/00128415-201213940-00129.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1159 (2007): 25. http://dx.doi.org/10.2165/00128415-200711590-00075.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1373 (2011): 27. http://dx.doi.org/10.2165/00128415-201113730-00091.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Prakash, Amitabh, and Diana Faulds. "Rabeprazole." Drugs 55, no. 2 (1998): 261–67. http://dx.doi.org/10.2165/00003495-199855020-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bank, Simmy. "Rabeprazole." Drugs 55, no. 2 (1998): 268. http://dx.doi.org/10.2165/00003495-199855020-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Takeguchi, Noriaki. "Rabeprazole." Drugs 55, no. 2 (1998): 268. http://dx.doi.org/10.2165/00003495-199855020-00011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Langtry, Heather D., and Anthony Markham. "Rabeprazole." Drugs 58, no. 4 (1999): 725–42. http://dx.doi.org/10.2165/00003495-199958040-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Carswell, Christopher I., and Karen L. Goa. "Rabeprazole." Drugs 61, no. 15 (2001): 2327–56. http://dx.doi.org/10.2165/00003495-200161150-00016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Baldwin, Claudine M., and Susan J. Keam. "Rabeprazole." Drugs 69, no. 10 (2009): 1373–401. http://dx.doi.org/10.2165/00003495-200969100-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1244 (2009): 38. http://dx.doi.org/10.2165/00128415-200912440-00113.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1256 (2009): 29. http://dx.doi.org/10.2165/00128415-200912560-00090.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1052 (2005): 17. http://dx.doi.org/10.2165/00128415-200510520-00054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1330 (2010): 31. http://dx.doi.org/10.2165/00128415-201013300-00106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1342 (2011): 28. http://dx.doi.org/10.2165/00128415-201113420-00100.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1422 (2012): 41–42. http://dx.doi.org/10.2165/00128415-201214220-00139.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Rabeprazole." Reactions Weekly &NA;, no. 1429 (2012): 35. http://dx.doi.org/10.2165/00128415-201214290-00132.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Aman, Kumar Singh*1 Alka Verma2 Ram Sevak Verma3 Ramnivas4 Suraj Mishra5 Pranjul Verma6. "Formulation of Dosage Forms with Rabeprazole: Challenges and Future Perspectives." International Journal in Pharmaceutical Sciences 2, no. 3 (2024): 932–46. https://doi.org/10.5281/zenodo.10868683.

Full text

Abstract:

Since its introduction in 1999 Rabeprazole is widely used Proton pump inhibitor for the treatment of a number of disease and conditions that are related to the excessive secretion of the gastric acid but still there is a strong need of a dosage form of rabeprazole that meets requirement of all age group of patients. There is a requirement of a stable formulation whose dose can be easily adjusted according to patient. The aim of this review is to describe the discovery and development of Rabeprazole, discuss the issues that arise during formulation of dosage form with rabeprazole and their poss

APA, Harvard, Vancouver, ISO, and other styles

20

Yadav, Shivanee, Harikrishna Yadav, Nidhi Tyagi, and Prashant Kumar Katiyar. "A Review on the Pharmacokinetics and Toxicological Profile of Rabeprazole." International Journal of Pharmaceutical Sciences and Medicine 9, no. 7 (2024): 24–36. http://dx.doi.org/10.47760/ijpsm.2024.v09i07.003.

Full text

Abstract:

Rabeprazole, a proton pump inhibitor, is used for individuals with ulcers. The prodrug is transformed into an active sulphenamide form by the acidic conditions present in the parietal cells. Rabeprazole inhibits the H+K+ ATPase of the gastric cells, leading to a decrease in the generation of stomach acid in both normal and stimulated situations. The present review was based on the pharmacokinetics and toxicological profile of Rabeprazole. Once absorbed into the body, approximately 96.3–97% of rabeprazole is bound to plasma proteins. In humans, the half-life of rabeprazole is approximately one

APA, Harvard, Vancouver, ISO, and other styles

21

Jia, Rong-Jie, Xiao-Peng Wang, Zhen-Hua Zhang, et al. "Effect of Rabeprazole and Rebamipide in the Treatment of Upper Gastrointestinal Hemorrhage Associated with Dual Antiplatelet Therapy in Elderly Patients with Coronary Heart Disease." Clinical and Applied Thrombosis/Hemostasis 28 (January 2022): 107602962211307. http://dx.doi.org/10.1177/10760296221130746.

Full text

Abstract:

To investigate the therapeutic effect of rabeprazole and rebamipide on patient age over 60 with dual antiplatelet therapy (DAPT)–related upper gastrointestinal hemorrhage following percutaneous coronary intervention (PCI). A total of 360 patients age over 60 undergoing PCI were recruited for antiplatelet therapy involving a combined treatment of aspirin (100 mg/d) and clopidogrel (75 mg/d). The enrolled patients were divided into 4 groups: the control group, the rabeprazole group, the rebamipide group, and the rabeprazole + rebamipide group. The incidence and severity of any upper gastrointest

APA, Harvard, Vancouver, ISO, and other styles

22

Gorakshanath, Ghugarkar Prasad, and Kadam Pallavi Kanifnath. "Design, Development and Physicochemical Evaluation of Formulation for Gastroesophageal Reflux Disease." International Journal of Drug Delivery Technology 15, no. 02 (2025): 01–05. https://doi.org/10.25258/ijddt.15.2.41.

Full text

Abstract:

The present study mainly involves the targeting the gastro intestinal ulcer by using Rabeprazole formulation. In this main strategy contains the formulation and optimisation of Rabeprazole pellet formulation. The stomach is the primary acidic environment in which nearly all drugs that inhibit proton pumps breakdown. The strategy involve is to coat the Rabeprazole pellet formulation with polymer coat which release the formulation in appropriate site only. Pre formulation date of material detected. Compatibility study of drug with selected excipients was analysed by using Fourier Transform Infra

APA, Harvard, Vancouver, ISO, and other styles

23

Lopina, O. D., B. K. Nurgalieva, and T. L. Lapina. "Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole." Russian Journal of Gastroenterology, Hepatology, Coloproctology 31, no. 4 (2021): 55–63. http://dx.doi.org/10.22416/1382-4376-2021-31-4-55-63.

Full text

Abstract:

Aim. A comparative review of the rabeprazole properties vs. other PPIs, its efficacy and safety in treatment for aciddependent diseases.Key points. Rabeprazole provides a rapid proton pump blockade in parietal cells due to its high dissociation constant (pKa). A lower rabeprazole metabolic dependence on cytochrome P-450 enzyme system renders its antisecretory effect predictable and reduces the risk of interactions with other drugs metabolised through this system. A faster antisecretory effect and higher acid-suppressive activity of rabeprazole determine its better clinical efficacy in treatmen

APA, Harvard, Vancouver, ISO, and other styles

24

&NA;. "Lansoprazole/rabeprazole." Reactions Weekly &NA;, no. 1097-1098 (2006): 18. http://dx.doi.org/10.2165/00128415-200610970-00057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

&NA;. "Rabeprazole/terbinafine." Reactions Weekly &NA;, no. 864 (2001): 11. http://dx.doi.org/10.2165/00128415-200108640-00029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

&NA;. "Aciphex (Rabeprazole)." Gastroenterology Nursing 23, no. 2 (2000): 88–89. http://dx.doi.org/10.1097/00001610-200003000-00011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Khokra, Sukhbir Lal, Balram Choudhary, and Heena Mehta. "RP-HPLC analysis for the simultaneous estimation of rabeprazole sodium and aceclofenac in a combined dosage form." International Current Pharmaceutical Journal 1, no. 12 (2012): 410–13. http://dx.doi.org/10.3329/icpj.v1i12.12450.

Full text

Abstract:

A rapid, simple and highly sensitive reversed phase high performance liquid chromatographic (RP-HPLC) method has been developed for the quantitative determination of Rabeprazole sodium and Aceclofenac in a combined dosage form. Rabeprazole sodium and Aceclofenac were chromatographed using C-18 column as stationary phase and methanol: acetonitrile: water (60 : 10 : 30 v/v/v) as the mobile phase at a flow rate of 1.0 ml/min at ambient temperature and detected at 280 nm. The retention time (RT) of Rabeprazole sodium and Aceclofenac were found to be 5.611 min and 2.102 minute, respectively. The li

APA, Harvard, Vancouver, ISO, and other styles

28

Jeong, Seung-Hyun, Ji-Hun Jang, and Yong-Bok Lee. "Exploring Differences in Pharmacometrics of Rabeprazole between Genders via Population Pharmacokinetic–Pharmacodynamic Modeling." Biomedicines 11, no. 11 (2023): 3021. http://dx.doi.org/10.3390/biomedicines11113021.

Full text

Abstract:

Rabeprazole is a proton pump inhibitor that inhibits gastric acid production and increases gastric pH; it is widely used clinically as a treatment option for gastritis and gastric ulcers. However, information on the inter-individual variability of rabeprazole pharmacometrics, which is a key element in establishing its scientific clinical use, is still lacking. Particularly, the differences in pharmacokinetics between genders and the degree of variation in pharmacodynamics have not been clearly identified. Thus, the main purpose of this study was to explore any differences in rabeprazole pharma

APA, Harvard, Vancouver, ISO, and other styles

29

Ashok, Agrawal. "Rabeprazole: The Unique PPIs." Clinical Endocrinology and Metabolism 2, no. 1 (2023): 01–04. https://doi.org/10.31579/2834-8761/014.

Full text

Abstract:

Rabeprazole is a proton pump inhibitor (PPI). Rabeprazole is a rapid and potent inhibitor of H+, K+-ATPase. Rabeprazole has many advantages over the other currently available proton pump inhibitors in terms of chemical activation rate, onset of action, degree of inhibition of gastric acid secretion, metabolism, and gastric mucus and mucin production. Current review article is undertaken to discuss these unique features.

APA, Harvard, Vancouver, ISO, and other styles

30

Oridate, Nobuhiko, Ryoji Tokashiki, Yusuke Watanabe, Aki Taguchi, Osamu Kawamura, and Kazuma Fujimoto. "Endoscopic Laryngeal Findings in Japanese Patients with Laryngopharyngeal Reflux Symptoms." International Journal of Otolaryngology 2012 (2012): 1–4. http://dx.doi.org/10.1155/2012/908154.

Full text

Abstract:

Objective. To know the characteristics of endoscopic laryngeal and pharyngeal abnormalities in Japanese patients with laryngopharyngeal reflux symptoms (LPRS).Methods. A total of 146 endoscopic images of the larynx and pharynx (60 pairs for the rabeprazole group and 13 pairs for the control group) were presented to 15 otolaryngologists blinded to patient information and were scored according to several variables potentially associated with laryngopharyngeal reflux. The median value of the 15 scores for each item from each image was obtained. The mean pretreatment scores of each item and total

APA, Harvard, Vancouver, ISO, and other styles

31

Polimeni, Giovanni, Paola Cutroneo, Adele Gallo, Salvatore Gallo, Edoardo Spina, and Achille P. Caputi. "Rabeprazole and Psychiatric Symptoms." Annals of Pharmacotherapy 41, no. 7-8 (2007): 1315–17. http://dx.doi.org/10.1345/aph.1k134.

Full text

Abstract:

Objective: To report the case of a patient who developed marked anxiety associated with episodes of panic attacks after starting rabeprazole therapy. Case Summary: An otherwise healthy 55-year-old woman was prescribed rabeprazole 20 mg/day administered in the morning tor persistent symptoms of dyspepsia. Ten days later, she presented with a 7 day history of marked anxiety associated with panic attacks, night terror (pavor nocturnus), episodic mental confusion, and attention deficit. Within 2 days of discontinuing rabeprazole, the patient recovered completely from the neuropsychiatric manifesta

APA, Harvard, Vancouver, ISO, and other styles

32

ZHU, Hai-di, Heng WANG, Xian-ming XIA, Shu-man XU, and Yao LAN. "Rabeprazole 10 mg versus 20 mg in preventing relapse of gastroesophageal reflux disease: a meta-analysis." Chinese Medical Journal 126, no. 16 (2013): 3146–50. http://dx.doi.org/10.3760/cma.j.issn.0366-6999.20130576.

Full text

Abstract:

Background Several randomized controlled trials (RCTs) have compared endoscopic and symptomatic relapses in patients with erosive gastroesophageal reflux disease (GERD). We have summarized current evidence for rabeprazole 10 or 20 mg once daily for GERD maintenance treatment over 1 or 5 years. Methods MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched, through August 2012, for eligible RCTs of adults with erosive GERD. The efficacies of rabeprazole 10 and 20 mg/d were compared. Results The search identified 288 citations, and five RCTs containing 1480 patient

APA, Harvard, Vancouver, ISO, and other styles

33

Somepalli, Alekhya, Nanda Gopala Krishna Gona, Sri lakshmi Avutu, Naga Sailaja Chandolu, Valli Padma Chilaka, and Sony Priyanka Arava. "A New RP-HPLC Method Development and Validation of Levosulpiride and Rabeprazole." International Journal for Research in Applied Science and Engineering Technology 11, no. 5 (2023): 1590–608. http://dx.doi.org/10.22214/ijraset.2023.51547.

Full text

Abstract:

Abstract: The Present study was conducted to obtain a new, affordable, cost-effective and convenient method for RP- HPLC determination of Rabeprazole and Levosulpiride in tablet dosage form. The experiment was carried out according to the official specifications of USP–30, ICH- 1996 and Global Quality Guidelines-2002.The method was validated for the parameters like system suitability , selectivity, linearity, accuracy, precision ,LOD, LOQ, and robustness. 20mg Rabeprazole and 75mg Levosulpiride was dissolve in 100 ml of Diluent (1:1,Methanol:Na2HPO4) and was further diluted to get stock soluti

APA, Harvard, Vancouver, ISO, and other styles

34

Trukhan, D. I., E. N. Degovtsov, and A. L. Mazurov. "Choice of protonic pump inhibitor with regard to multimorbidity: a focus on rabeprazol." Medical Council, no. 3 (May 12, 2019): 34–42. http://dx.doi.org/10.21518/2079-701x-2019-3-34-42.

Full text

Abstract:

Acid-related diseases occupy a leading place in the structure of the incidence of the gastrointestinal tract. One of the important aspects of studying them now is to consider them in combination with coronary heart disease, hypertension, diabetes, asthma and other common diseases and conditions. Proton pump inhibitors are currently the basis for the treatment of acid-related diseases. Although all PPIs are very effective, the antisecretory effects of various drugs of this class may differ in different patients, especially in the presence of comorbidities and comorbidities. The pharmacokinetics

APA, Harvard, Vancouver, ISO, and other styles

35

Evans, Charity, Gordon Stueck, Sandhya Koobair, Jaimala Maharaj, and Vikesh Maraj. "Patient Acceptance and Economic Outcomes of Rabeprazole Therapy — A Pharmacist-Initiated Interchange Protocol." Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 138, no. 5 (2005): 44–49. http://dx.doi.org/10.1177/171516350513800505.

Full text

Abstract:

Objective: The purpose of this study was to measure the patient acceptance, as well as the individual and provincial cost savings, of switching from other proton pump inhibitor (PPI) therapies to the less costly rabeprazole. Design and setting: This was an uncontrolled, prospective study conducted at a community pharmacy in conjunction with the physicians at the local medical clinic. Patients: Male and female patients over 18 years of age who were currently taking a PPI (omeprazole, lansoprazole, pantoprazole) regularly and who were under the care of a participating physician were eligible. Pa

APA, Harvard, Vancouver, ISO, and other styles

36

Dewan, Bhupesh, and Nisha Philipose. "Lafutidine 10 mg versus Rabeprazole 20 mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: A Randomized, Multicentric Trial." Gastroenterology Research and Practice 2011 (2011): 1–8. http://dx.doi.org/10.1155/2011/640685.

Full text

Abstract:

Background. Empirical therapy with antisecretory agents like PPIs and H2RAs has long been the traditional approach in the initial management of uninvestigated dyspepsia.Aim. The objective of the study was to examine relief of dyspepsia with lafutidine, a second-generationH2-RA, and rabeprazole and to compare their efficacy.Methods. This was a randomized, open, comparative trial in adult uninvestigated dyspeptic patients, who had at least moderate severity of symptoms, defined as a score of≥4 on a 7-point global overall symptom (GOS) scale, and were randomized to receive once daily either lafut

APA, Harvard, Vancouver, ISO, and other styles

37

&NA;. "Lansoprazole/omeprazole/rabeprazole." Reactions Weekly &NA;, no. 1161 (2007): 16. http://dx.doi.org/10.2165/00128415-200711610-00051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

&NA;. "Antirheumatics/bisphosphonates/rabeprazole." Reactions Weekly &NA;, no. 1403 (2012): 8. http://dx.doi.org/10.2165/00128415-201214030-00018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Hsu, Ping-I., Chien-Lin Chen, Chih-An Shih, et al. "Vonoprazan High-dose Dual, Vonoprazan Triple and Rabeprazole Reverse Hybrid Therapies for First-line Treatment of H. pylori Infection: A Multicenter Randomized Trial." American Journal of Gastroenterology, June 25, 2025. https://doi.org/10.14309/ajg.0000000000003607.

Full text

Abstract:

OBJECTIVES: The study aimed to compare the efficacy of 14-day vonoprazan high-dose dual, vonoprazan triple and rabeprazaole reverse hybrid therapies for the first-line treatment of H. pylori infection. METHODS: In the multi-center, randomized, open-label trial, we consecutively recruited adult H. pylori-infected patients from six centers in Taiwan. Subjects were randomly assigned (1:1:1) to 14-day vonoprazan high-dose dual, vonoprazan triple or rabeprazole reverse hybrid therapy. Eradication status was determined by 13C-urea breath test. The primary outcome was the eradication rate of H. pylor

APA, Harvard, Vancouver, ISO, and other styles

40

"Rabeprazole." Reactions Weekly 1853, no. 1 (2021): 415. http://dx.doi.org/10.1007/s40278-021-95281-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

"Rabeprazole." Reactions Weekly 1920, no. 1 (2022): 414. http://dx.doi.org/10.1007/s40278-022-21951-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

"Rabeprazole." Reactions Weekly 1881, no. 1 (2021): 226. http://dx.doi.org/10.1007/s40278-021-05435-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

"Rabeprazole." Reactions Weekly 1876, no. 1 (2021): 289. http://dx.doi.org/10.1007/s40278-021-03538-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

"Rabeprazole." Reactions Weekly 2019, no. 1 (2024): 400. http://dx.doi.org/10.1007/s40278-024-64313-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

"Rabeprazole." Reactions Weekly 1693, no. 1 (2018): 434. http://dx.doi.org/10.1007/s40278-018-43324-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

"Rabeprazole." Reactions Weekly 1707, no. 1 (2018): 237. http://dx.doi.org/10.1007/s40278-018-48053-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

"Rabeprazole." Reactions Weekly 1642, no. 1 (2017): 262. http://dx.doi.org/10.1007/s40278-017-27439-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

"Rabeprazole." Reactions Weekly 1577, no. 1 (2015): 218. http://dx.doi.org/10.1007/s40278-015-10631-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

"Rabeprazole." Reactions Weekly 1656, no. 1 (2017): 393. http://dx.doi.org/10.1007/s40278-017-31721-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

"Rabeprazole." Reactions Weekly 1526, no. 1 (2014): 116. http://dx.doi.org/10.1007/s40278-014-4763-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!